Research collaborators: Mayo Clinic · University of Minnesota · NYU Langone Health
Poor sleep and cognitive decline feed each other.
Deep, slow-wave sleep is when the brain consolidates memory and clears metabolic waste. As we age, that sleep erodes. Lost sleep accelerates cognitive decline, and cognitive decline further disrupts sleep. Current options, from sedative medications to behavioral programs, often fall short for older adults.
Synaptic Health is building therapies designed to break this cycle, drug-free and at home.
10–12M U.S. adults have chronic insomnia severe enough to warrant treatment.(1)
~7M Americans are living with Alzheimer's disease.(2)
20–40% of people with mild-to-moderate Alzheimer's experience significant sleep disturbance.(3)
A sleep mask that listens before it acts.
Our lead platform, the TRS (thermoregulatory stimulation) sleep mask, combines embedded EEG sensing with an adaptive AI controller. It delivers brief, gentle thermal cues timed to the brain's real-time state: first to guide the user into deep, slow-wave sleep, then to keep them there longer, without waking them.
01 Sense
Comfortable embedded EEG reads brain activity continuously through the night.
04 Adapt
An AI-adaptive controller learns each user's response and personalizes therapy night over night.
02 Detect
On-device algorithms track sleep stage in real time and find the right moments to intervene.
Non-invasive & drug-free
No implants, no medication. Designed for nightly use at home.
03 Stimulate
Gentle thermal cues around the eyes and forehead induce slow-wave sleep, then prolong it.
Personalized by design
Therapy adapts to each individual's physiology rather than following a fixed schedule.
The TRS platform:
from sleep science to a working system
The TRS platform brings sensing, decision-making and stimulation together in a single wearable, so therapy responds to each night of sleep as it happens.
Integrated wearable: EEG sensing and thermal stimulation in one comfortable mask, paired with a bedside hub.
Real-time closed loop: sensing, decisions and stimulation run continuously through the night and adapt as sleep changes.
Clear regulatory path: designed for an FDA 510(k) pathway, starting with insomnia as our lead indication.
Pipeline: one platform, multiple sleep indications.
We are advancing the TRS platform toward FDA clearance for insomnia, while exploring sleep-based approaches for people living with cognitive impairment.
TRS Sleep Mask: Insomnia (lead program). Closed-loop thermal stimulation, intended 510(k) pathway. Stage: prototype verification.
TRS Sleep Mask: MCI & Alzheimer's. Enhancing slow-wave sleep in cognitive impairment. Stage: research.
Soundly: Obstructive Sleep Apnea. Gamified myofunctional therapy app, Software as a Medical Device. Stage: feasibility study complete.
Soundly Reduce Snoring. Consumer wellness app for iOS. Available now.
Investigational device. The TRS sleep mask is in development and has not been cleared or approved by the U.S. Food and Drug Administration. It is not available for sale. Soundly Reduce Snoring is a consumer wellness product and is not intended to diagnose or treat any disease.
Built on peer-reviewed research.
Our programs build on published clinical evidence and on studies run with leading academic sleep medicine centers.
48%: Thermal cues speed sleep onset. In a 106-patient randomized trial, a forehead thermal device reduced sleep-onset latency in people with insomnia. That finding is the scientific basis for our approach. (Roth T. et al., Sleep, 2018; third-party study)
22%: Snoring reduction with Soundly. A randomized pilot trial found that gamified oropharyngeal exercises reduced snoring compared with controls. (Goswami U. et al., Sleep and Breathing, 2019)
78% vs 58%: Higher adherence with gamification. In a 30-participant feasibility study at Mayo Clinic, people with obstructive sleep apnea stuck with gamified therapy more consistently than with standard therapy. (Feasibility study, Mayo Clinic Arizona)
Leadership: scientists and builders who have done this before.
Brian Krohn, PhD, Co-Founder & Chief Executive Officer. Former Innovation Fellow at the University of Minnesota Medical Devices Center. Brian previously built and exited a digital health company. He holds a PhD from the University of Minnesota and two MSc degrees from the University of Oxford.
Bryce Beverlin II, PhD, Co-Founder & Chief Scientific Officer. A physicist with more than 15 years in closed-loop neuromodulation, including deep-brain stimulation for epilepsy, and co-inventor on Boston Scientific patents. He holds a PhD in physics and biomedical engineering from the University of Minnesota.
Research collaborators:
Mayo Clinic: sleep medicine and clinical research collaboration.
University of Minnesota: sleep neurology, biomedical engineering and AI/ML.
NYU Langone Health: sleep and Alzheimer's disease research.
Work with us
Clinicians & researchers: explore research collaborations, clinical study sites and data partnerships.
Investors & strategic partners: learn about our platform, regulatory strategy and growth plans.
Patients & caregivers: join our mailing list to hear about future studies and product updates.
Let's restore sleep together.
Clinicians, researchers, investors, partners, patients and caregivers: we'd like to hear from you. Based in Minneapolis, Minnesota, in the heart of Medical Alley.
Important information
CAUTION: The TRS sleep mask is an investigational device that has not been cleared or approved by the FDA. Information on this website is not medical advice.
References: (1) Riemann D. et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017. (2) Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. (3) [ADD SOURCE for 20-40% sleep disturbance in mild-to-moderate AD]
© 2026 Synaptic Health LLC. All rights reserved.